Complement Inhibition in aHUS Dialysis Patients

Key facts

Sponsor

Mario Negri Institute for Pharmacological Research

Principal Investigator

Giuseppe Remuzzi, MD

IRCCS - Mario Negri Institute for Pharmacological Research/A.O. Papa Giovanni XXIII- BG

Intervention

CCX168(drug)

Enrollment

6 enrolled

Eligibility

18 years · All sexes

Timeline

2015 – 2017

Study locations (1)

• A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/IRCCS IRFMN - Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Bergamo, Italy

Collaborators

Amgen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Atypical hemolytic uremic syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT07308574
  Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
  Alexion Pharmaceuticals, Inc.
• RECRUITINGNANCT07218536
  The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt
  AstraZeneca
• RECRUITINGPHASE3NCT05935215
  Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
  Novartis Pharmaceuticals
• ACTIVE NOT RECRUITINGNCT06099236
  A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
  AstraZeneca
• ACTIVE NOT RECRUITINGNANCT05985122
  New Analytic Tools for aHUS and C3G Diagnosis
  Mario Negri Institute for Pharmacological Research
• RECRUITINGNANCT05805202
  Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy
  Mario Negri Institute for Pharmacological Research
• ACTIVE NOT RECRUITINGPHASE3NCT04958265
  A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
  Hoffmann-La Roche
• ACTIVE NOT RECRUITINGPHASE3NCT04861259
  A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
  Hoffmann-La Roche

See all trials for Atypical hemolytic uremic syndrome →